Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816630 · ClinicalTrials.gov registry record
Feasibility Study of Hematology Parameters in COVID-19 Disease
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 32
- Enrollment target
NCT04816630 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 32 participants.
The verdict
NCT04816630 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care includes CBC-DIFF and microbial testing.
Interventions
- DEVICE CBC-Diff Monocyte Volume Width Distribution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2021-09-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04816630
The ClinicalTrials.gov registry entry for NCT04816630 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beckman Coulter, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBC-Diff Monocyte Volume Width Distribution is the first listed.
NCT04816630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04816630 about?
NCT04816630 is a clinical study titled "Feasibility Study of Hematology Parameters in COVID-19 Disease". The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care includes CBC-DIFF and m...
What is the current status of trial NCT04816630?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2020-12-21. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT04816630?
The interventions under investigation include: CBC-Diff Monocyte Volume Width Distribution (DEVICE).
Who is sponsoring clinical trial NCT04816630?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.